Literature DB >> 3143306

Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.

J Fung-Tomc1, E Huczko, M Pearce, R E Kessler.   

Abstract

The selection frequencies of cefepime (BMY 28142), ceftazidime, and cefotaxime resistance among Pseudomonas aeruginosa strains were determined. Cefepime-resistant mutants were not selected by cefepime (frequency, less than 10(-11)). Ceftazidime- and cefotaxime-resistant mutants were isolated at frequencies of 10(-5) to 10(-10) and were often cross-resistant. However, cefepime resistance among ceftazidime- and cefotaxime-resistant mutants was rare. Selected mutants resistant to cefepime constitutively produced 40- to 450-fold more beta-lactamase than did the parent strain.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3143306      PMCID： PMC175888          DOI： 10.1128/AAC.32.9.1443

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Synergistic resistance mechanisms in Pseudomonas aeruginosa.

Authors:  C W Stratton; F Tausk
Journal:  J Antimicrob Chemother       Date:  1987-04       Impact factor: 5.790

2.  Novel plasmid-mediated beta-lactamase in clinical isolates of Klebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins.

Authors:  A Petit; D L Sirot; C M Chanal; J L Sirot; R Labia; G Gerbaud; R A Cluzel
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

3.  A spectrophotometric assay of beta-lactamase action on penicillins.

Authors:  S G Waley
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

4.  Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

5.  Evolution of plasmid-coded resistance to broad-spectrum cephalosporins.

Authors:  C Kliebe; B A Nies; J F Meyer; R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

6.  Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.

Authors:  M D Kitzis; D Billot-Klein; F W Goldstein; R Williamson; G Tran Van Nhieu; J Carlet; J F Acar; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

7.  A direct spectrophotometric assay and determination of Michaelis constants for the beta-lactamase reaction.

Authors:  A Samuni
Journal:  Anal Biochem       Date:  1975-01       Impact factor: 3.365

8.  Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.

Authors:  D J Phelps; D D Carlton; C A Farrell; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

9.  Development of beta-lactam-resistant Enterobacter cloacae in mice.

Authors:  B Marchou; M Michea-Hamzehpour; C Lucain; J C Pechère
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

10.  Susceptibility to penicillins and cephalosporins in beta-lactamase producing strains of E. coli and relative amount of beta-lactamase produced from these strains.

Authors:  S Normark; T Grundström; S Bergström
Journal:  Scand J Infect Dis Suppl       Date:  1980
View more
  12 in total

1.  Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.

Authors:  J A Bosso; B A Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Reverse engineering antibiotic sensitivity in a multidrug-resistant Pseudomonas aeruginosa isolate.

Authors:  Julie M Struble; Ryan T Gill
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Low-level resistance to the cephalosporin 3'-quinolone ester Ro 23-9424 in Escherichia coli.

Authors:  J S Chapman; A Bertasso; L M Cummings; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

4.  Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.

Authors:  R H Barbhaiya; S T Forgue; C R Gleason; C A Knupp; K A Pittman; D J Weidler; H Movahhed; J Tenney; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

5.  Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.

Authors:  D Voutsinas; T Mavroudis; A Avlamis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 6.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.

Authors:  L O Gentry; G Rodriguez-Gomez
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 8.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

9.  Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

Authors:  J Fung-Tomc; T J Dougherty; F J DeOrio; V Simich-Jacobson; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 10.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.